The 340B Software Stack: The Next Healthcare SaaS Vertical
Table of Contents
How 340B Became a Software Problem
The Eligibility Engine Layer
Split Billing and the Reconciliation Stack
Manufacturer Compliance and the Dispute Layer
Specialty Pharmacy Optimization Software
The Platform Play and What Comes Next
Abstract
- 340B Drug Pricing Program generates an estimated $44-54B in covered entity savings annually (HRSA 2023 data, various estimates)
- Program complexity has quietly produced a dedicated SaaS vertical analogous to early revenue cycle management software
- Six discrete software categories have emerged, each representing a standalone venture opportunity
- Manufacturer restrictions since 2020 have massively accelerated software demand across the stack
- The vertical is fragmented, underleveraged on AI/ML, and early in consolidation
How 340B Became a Software Problem
The 340B Drug Pricing Program was signed into law in 1992 as part of the Veterans Health Care Act. The original intent was simple enough – qualifying covered entities, mostly safety-net hospitals and federally qualified health centers, could purchase outpatient drugs at significantly reduced prices, with the spread theoretically subsidizing care for low-income and uninsured patients. For about the first fifteen years of the program’s life, the operational complexity was manageable. Covered entities had relatively limited formularies, contract pharmacy arrangements were rare, and the program’s administrative footprint was small enough that a decent pharmacist and a spreadsheet could handle most of the compliance work.
That era ended somewhere around 2010, and the catalysts were structural. The Affordable Care Act dramatically expanded the universe of eligible covered entities and, more importantly, exploded the volume of eligible patients moving through qualifying facilities. At the same time, the commercial specialty pharmacy market was exploding. Biologic therapies, oncology agents, and specialty injectables – drugs carrying average wholesale prices measured in thousands of dollars per unit – were becoming a larger share of total drug spend. The intersection of those two dynamics turned 340B from a modest safety-net benefit into one of the largest drug pricing mechanisms in the U.S. system. By the mid-2010s, covered entities were purchasing somewhere between 5% and 6% of all outpatient drugs in the country through 340B channels. That share has since grown.
The contract pharmacy expansion was the decisive inflection point from a software perspective. HRSA’s 2010 guidance allowed covered entities to use an essentially unlimited number of contract pharmacy arrangements, meaning a qualifying hospital could register retail pharmacies across a geographic footprint as dispensing sites for 340B-purchased drugs. That ruling turned the program into a distributed financial network almost overnight. A mid-sized academic medical center might now manage hundreds of contract pharmacy locations, each requiring patient eligibility verification, prescription attribution, drug replenishment tracking, and split billing reconciliation. The data flows involved in running that network properly at scale are genuinely complex – on par with the transaction processing infrastructure behind a regional health plan.
The analogy to revenue cycle is not cosmetic. Revenue cycle management software emerged because billing and collections in healthcare became too operationally complex to handle through manual processes or generic accounting tools. The same dynamic is now playing out in 340B. The program’s rules are byzantine, the data requirements are substantial, and the financial stakes are high enough that errors are expensive in both directions. An eligibility misclassification that allows a non-qualifying prescription to accumulate 340B savings is a compliance liability. A reconciliation failure that lets contract pharmacy claims go unmatched means leaving real money on the table. The covered entity operating a serious 340B program today needs purpose-built tooling, and a generation of startups has been building it.
The Eligibility Engine Layer
